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Cysteine proteases play a key role in tumorigenesis causing protein degradation and promoting invasive
tumour growth. Cathepsin L is overexpressed in cancer cells and could provide a speciﬁc target for
delivery of anticancer agents. We encapsulated novel dipeptidyl nitrile based cysteine protease inhibitors
(Neq0551, Neq0554 and Neq0568) into biocompatible apoferritin (AFt) protein nanocages to achieve
speciﬁc delivery to tumours and pH-induced drug release. AFt-encapsulated Neq0554 demonstrated
3-fold enhanced in vitro activity (GI50 ¼ 79 mM) compared to naked agent against MiaPaCa-2
pancreatic carcinoma cells. Selectivity for cancer cells was conﬁrmed by comparing their activity to non-
tumourigenic human ﬁbroblasts (GI50 > 200 mM). Transferrin receptor (TfR-1) expression, detected only
in lysates prepared from carcinoma cells, may contribute to the cancer-selectivity. The G1 cell cycle
arrest caused by AFt-Neq0554 resulting in cytostasis was corroborated by clonogenic assays. Superior
and more persistent inhibition of cathepsin L up to 80% was achieved with AFt-encapsulated agent in
HCT-116 cells following 6 h exposure to 50 mM agent. The selective anticancer activity of AFt-
encapsulated cysteine protease inhibitor Neq0554 reported here warrants further preclinical in vivo
evaluation.Introduction
Proteases are essential for cell survival and development and
play important roles in cellular proliferation, migration, adhe-
sion, senescence, autophagy, apoptosis and immune system
evasion.2 To date, proteases were considered as potential targets
for the treatment of diseases, such as Chagas disease,3 leish-
maniosis,4 osteoporosis5 and some types of carcinomas.6–8
Predominantly found in the intracellular environment, these
enzymes are abundantly localized in the lysosomes of normal
cells.9 However, some proteases are also present in the extra-
cellular medium, assisting extracellular matrix degradation in
cancer.2,10
Cathepsin L, a lysosomal cysteine protease, is a marker for,
and overexpressed in pancreatic cancer.11,12 Because of thePharmacy, University of Nottingham, NG7
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hemistry 2019aggressive nature of pancreatic cancers, >80% of patients
present with metastatic disease and 5 years survival is dismal,
8%.10,13 Colorectal adenocarcinoma (CRC) also represents an
aggressive, chemotherapy-resistant disease.14 With high meta-
static incidence (>50% patients) and poor prognosis associated
with late stage disease (5 years survival stage IV CRC < 8%),
therapeutic intervention has limited success.14 Cellular dereg-
ulation of cathepsin L expression is one of the common char-
acteristics of these types of carcinomas, as well as elevated
extracellular levels.15,16 Inhibition of cathepsin L could oﬀer
a route for treatment of these cancers. Recently, elevated cath-
epsin L activity has been reported in murine models with
pancreatic cancer, with reduction in the tumour size aer its
gene deletion.13 Cathepsin L inhibition by covalent inhibitors
was shown to suppress proliferation of pancreatic cancer cells,11
and colorectal adenocarcinoma cells.14
Reversible covalent inhibitors are known to be a viable
approach to decrease side eﬀects associated with the oﬀ-target
eﬀects inside the cells.17 However, all types of covalent inhibi-
tors need to position the reactive group in the vicinity of the
cysteine amino acid in the catalytic pocket, thus leading to the
necessity to design compounds with substituents that t the
subsites of the enzyme counterpart mimicking a peptide (pep-
tidomimetics). One of the promising groups of peptidomimetic
agents are dipeptidyl nitrile reversible covalent cysteine
protease inhibitors with high-aﬃnity for the target enzyme andRSC Adv., 2019, 9, 36699–36706 | 36699
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ciency.18,19 Cathepsin L possesses important functions in
normal cells, and its inhibition could cause adverse toxicities
limiting therapeutic eﬃcacy. Hence new formulations are
needed to ensure selective or preferential uptake by cancer cells.
The apoferritin (AFt) nanocapsule has been identied as an
ideal drug delivery vehicle20 and has been used to encapsulate
proteins and small drug molecules.21–24 AFt is internalized into
cells by transferrin receptor 1 (TfR1)-mediated endocytosis;
TfR1 is upregulated and highly expressed on cancer cell
membranes.25 Also, enhanced delivery and uptake to cancer
tissues is expected due to enhanced permeability and retention
(EPR) associated with the tumour microenvironment.26 In the
cells, AFt is traﬃcked to lysosomes, where increased acidity will
increase the protein pore size releasing the cargo.24 Since
cathepsin L is found predominately within lysosomes, AFt could
oﬀer great potential for selective delivery of cysteine protease
inhibitors.
Here we report the development of a new formulation of
dipeptidyl nitrile derivatives for selective targeting to cancer
cells and pH dependent drug release. We encapsulated cysteine
protease inhibitors (Neq0551, Neq0554 and Neq0568) within
AFt protein cages, demonstrating retention of AFt capsule
structural integrity and formulation stability. Investigation of
AFt formulations in physiologically relevant conditions revealed
enhanced drug release under acidic pH 5.5, associated with
tumour microenvironments, compared to neutral pH 7.4. In
vitro assessment of antitumor activity of naked and AFt-
encapsulated agents against pancreatic and colorectal cancer
cells was performed, conrming cancer-selectivity and
enhanced potency of the developed formulation of these
inhibitors. Our results provide the rst demonstration of the
potential of AFt for targeted delivery of cysteine protease
inhibitors to cancer cells, relevant for their applications as
anticancer agents in clinic.
Materials and methods
Preparation and characterization of encapsulated compounds
All the covalent reversible cysteine protease inhibitors were
synthesized as previously reported.18 Agents, with purity >95%
according to HPLC-MS analysis, were selected based on their
biochemical potential to inhibit cysteine proteases in the
nanomolar range. Horse spleen AFt was diluted in sodium
acetate buﬀer 100 mM pH 5.5 at 6  109 as nal numbers of
moles and kept at 4 C. Every 45 min, the drugs dissolved in
dimethylsulfoxide (DMSO) at the stock concentration of 50 mM
were gently added into the AFt solution to give a nal ratio of
1 : 500 (AFt : drugs). Un-encapsulated compound was removed
from solution by ultracentrifugation using Amicon membranes
30 kDa (13 000 rpm, 4 min, 4 C). Neq compound concentration
aer purication of AFt-encapsulated compound was deter-
mined by UV-Vis absorbance at 248 nm using a Thermo Fisher
Scientic NanoDrop™ 2000/c Spectrophotometer; the Beer–
Lambert law was used to quantify encapsulation. Total protein
concentration was determined using the Bradford assay.27
Encapsulation eﬃciency (EE%) is calculated as the percentage36700 | RSC Adv., 2019, 9, 36699–36706of drug that is successfully entrapped into the apoferritin with
respect to the drug added. Drug loading (DL%) is calculated as
the amount of drug loaded with respect to the total weight of the
nanoparticle (apoferritin and encapsulated drug molecules).
All encapsulated drugs were aliquoted and stored at 4 C pH
5.5 and stability was examined throughout 6 weeks by UV-Vis
spectroscopy. The physical properties of AFt were character-
ized by DLS and zeta-potential (using 1 mL of 0.2 mg mL1 AFt-
encapsulated agent). Native PAGE was conducted to conrm AFt
protein structure aer encapsulation. Proteins, 15 mL AFt solu-
tions (0.2 mg mL1) were separated on a 4–16% gradient gel
(Novex) at 4 C using cathodic and anodic buﬀers. Proteins were
stained following immersion of gels in Coomassie brilliant blue
for 1 h and washed with deionized water before capture of
images using Gene ow limited. Drug release was analyzed in
vitro in acidic (sodium acetate 100 mM pH 5.5) and neutral
(Hepes buﬀer 100mM pH 7.4) pH conditions. A dialysis method
was selected using a dialysis membrane (cut-oﬀ 8 kDa) for 24 h
at 37 C. At diﬀerent time points, drug release was determined
by UV-Vis, considering the initial concentration of encapsulated
drug as 100%.
In vitro studies
HCT-116 (hMLH1-) colorectal carcinoma cells and MiaPaCa-2
pancreatic adenocarcinoma cells were purchased from the
American type culture collection (ATTC) and grown in RPMI-
1640 medium supplemented with 10% foetal bovine serum
(FBS). For MRC-5 human broblast cells, DMEM medium
modied with 1% antibiotics, 1% non-essential amino acids,
5 mM L-glutamine, 1 mM HEPES buﬀer and 10% FBS was used.
All cell lines were grown at 37 C, 5% CO2 and used for the
assays aer achieving 70% conuence. The MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay
was used for cell growth and viability determination of normal
and cancer cell lines aer treatment with naked and encapsu-
lated drugs at diﬀerent concentrations. Cells were seeded into
96-well plates at density of 3  103 per well. The MTT reduction
at the time of drugs' addition (T0) and following 72 h exposure
was assessed to determine growth inhibitory eﬀects.
The clonogenic cell survival test was adopted to determine
the ability of single cells to survive a brief exposure to test agents
and maintain proliferative potential to form progeny colonies.
For this study, the cells (300 per well) were seeded into 6-well
plates and test agent treatment was performed for 24 h using
naked and encapsulated compounds at 10 mM and 100 mM.
Aer 7 days of incubation, colonies were stained with 0.5%
methylene blue.
Cell cycle study
For cell cycle analysis cell were seeded in 6 well plates at
a seeding density of 5  105 cells per well in 2 mL medium.
Following treatment with naked and encapsulated Neq0554 at
nal concentration of 10 mM and 100 mM, cells were pelleted by
centrifugation then resuspended in 0.5 mL uorochrome
solution 50 mg mL1 propidium iodide (PI), 0.1 mg mL1 ribo-
nuclease A, 0.1% v/v Triton X-100, and 0.1% w/v sodium citrateThis journal is © The Royal Society of Chemistry 2019
Fig. 1 (a) Chemical structures of the test agents. (b) A schematic
representation of encapsulated agent, Neq0554-AFt. (c) A photograph
of native PAGE of AFt and AFt-encapsulated agents. (d) Drug release
proﬁle for Neq0554-AFt at pH 5.5 and pH 7.4 at T ¼ 37 C.
Paper RSC Advancesin deionized water (dH2O). Cell suspensions were kept over-
night at 4 C protected from light. Cell cycle analyses were
performed on a Beckman Coulter FC500 ow cytometer. EX-
PO32 soware was used to analyze data.
Enzymatic studies
Cathepsin L isolated from human liver (Enzo life sciences) was
assayed uorometrically using the system Biotek Synergy HT at
25 C with a uorescence emission of 460 nm (excitation of 355
nm) over 5 minutes. The hydrolysis rate of the uorogenic
substrate Z-Phe-Arg-7-amido-4-methylcoumarin (Z-FR-MCA,
Sigma-Aldrich) was monitored. Enzyme kinetic assays were
carried out in Corning 96-well black at bottom microplates
containing 200 mL of a solution constituted by 100 mM acetate
buﬀer pH 5.5, 300 mM NaCl, 7 mM DTT (dithiothreitol), 5% v/v
DMSO, 0.01% v/v TritonX-100 and 1.9 nM hCat-L. The enzyme
was activated for 20 min in the assay buﬀer (100 mM acetate pH
5.5 and 7 mM DTT) before the reaction started. The substrate Z-
FR-MCA was prepared with a nal concentration of 10.9 mM (¼4
 KM). Stock solutions of the inhibitors were prepared in DMSO
with initial concentrations varying from 1 to 10 mM. The assay
was performed in triplicate. Analysis and manipulation of the
data were performed with Origin Pro 8.5. Each experiment was
performed in triplicate for each substance. Initial velocities of
the substrate hydrolysis under the rst-order reaction were
calculated using Gen5™ Biotek soware. The apparent inhibi-
tion constant K 0i was determined by non-linear regression using
equation Vs ¼ Vo=ð1þ ½I=K 0i Þ, where Vs is the steady-state rate,
Vo is the rate in the absence of inhibitor, and [I] is the inhibitor
concentration. The true inhibition constant Ki was calculated by
the correction of K 0i according to Ki ¼ K 0i=ð½S=KMÞ, where [S] is
the substrate concentration and KM is the Michaelis constant.
Western blot
Cells were cultured in 75 cm2 asks at 37 C, 5% CO2 until
70% conuent. Cells were then detached by trypsin and lysed
using lysis buﬀer (100mL NP40, 1 MNaCl, 1 M Tris–HCl pH 8.0)
supplemented with a protease inhibitor cocktail (Roche).
Cellular proteins (50 mg) were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and
electro-transferred onto PVDF membranes blocked in Tris-
buﬀered saline (TBS) solution containing 5% milk at room
temperature. Membranes were incubated in primary antibodies
(1 Abs; GAPDH and TfR-1) overnight at 4 C. Membranes were
then washed with TBS solution at room temperature and
incubated with a secondary (2) Ab (GE) for 1 h. Detection was
performed with Super Signal chemiluminescent reagent
according to the manufacturer's protocol (Tanon, China).
Confocal uorescence microscopy
Cells were seeded into 96-well black plates at a density of 104
cells per well and treated with 100 mM of naked and encapsu-
lated compounds for 24 h. Cells were washed with PBS and
incubated for 1 h with 300 diluted Red Magic Substrate
(Sigma-Aldrich) and Hoechst as a nuclear marker. Fluorescence
images were acquired with a confocal microscope Ultra NikonThis journal is © The Royal Society of Chemistry 2019equipped with a 40 objective with excitation lters at 510–
560 nm. Fluorescence emission was detected using bandpass
lter at 570–620 nm. Non-treated cells and cells treated with AFt
alone were used as negative controls.
Results
Encapsulation and characterization of AFt-Neq test agents
The dipeptidyl nitriles derivatives were synthesized as described18
and agents were selected for this study based on their biochem-
ical potential to inhibit cysteine proteases in the nanomolar
range. Three reversible covalent cysteine protease inhibitors





methyl)-4-methylpentanamide) (Fig. 1a). All agents were encapsu-
lated into the AFt cage by passive diﬀusion through the six
hydrophobic channels in the protein cage (Fig. 1b).28
For encapsulations, all agents were dissolved in DMSO (10
mM). Horse spleen AFt was prepared with a concentration of
5 mM and was dialyzed against sodium acetate buﬀer (pHRSC Adv., 2019, 9, 36699–36706 | 36701
Fig. 2 Western blot image revealing expression of transferrin receptor
(TfR1) in MiaPaCa-2 and HCT-116 cancer cells (a). Dose response
proﬁles of naked- and AFt-encapsulated Neq0554 in (b) HCT-116, (c)
MiaPaCa-2 cancer cells and (d) MRC-5 ﬁbroblasts. Cell viability assays
were performed in triplicate (n¼ 4 per trial) and the standard deviation
(SD) is shown. Lines are a guide to the eye.
RSC Advances Paper5.5). For encapsulation, 100 mL of agent was added ten times
(with intervals of 45 min between additions) to 1 mL of apo-
ferritin under constant mixing at 4 C. The nal molar ratio of
AFt : agent was 1 : 500. The encapsulation of test agents was
assessed by UV-Vis and the drug concentration was quantied
according to the Beer–Lambert law.
The mean numbers of encapsulated Neq0554 and Neq0551
molecules were 105 and 117, respectively, corresponding to
encapsulation eﬃciencies (EE) > 50% and drug loading >10%.
For Neq568, the EE was 71% and the mean number of mole-
cules encapsulated was 226 (Table 1).
Following encapsulation, AFt retained its structural integrity,
as conrmed by native PAGE29 and dynamic light scattering
(DLS), revealing the AFt band corresponding to MW  480 kDa
(Fig. 1b) and protein cage diameter of 13 nm (Fig. 1c),
respectively, as expected for AFt.30 The value of the zeta-
potential measured for AFt alone was 8.6  0.8 meV, and
was not changed following encapsulation of test agents (8.6 
0.7meV for Neq0554-AFt,8.5 0.5meV for Neq0551-AFt,8.9
 0.2 meV for Neq0568-AFt). These results conrm that the
agents are encapsulated predominantly inside the AFt cavity.
We have studied the release rate for all our encapsulated agents
at physiologically relevant pH 7.4 and pH 5.5. We observed
markedly more rapid release of cargo at pH 5.5 compared to
physiological pH 7.4, with corresponding out-diﬀusion of
Neq0554 > 75% and 32% respectively aer 12 h dialysis
(Fig. 1d). This trend was observed for all test agents (Fig. SI-2†).
In addition, at pH 5.5, initial fast release was more evident with
>50% compound liberated in the rst 6 h.Biological activity of AFt-Neq test agents
The therapeutic activity of the test agents and their encapsu-
lated formulations was evaluated in vitro. For these studies the
following cell lines were selected: HCT-116 (CRC) and MiaPaCa-
2 (pancreatic) carcinoma cell lines, MRC-5 foetal broblasts
representative of a non-transformed phenotype. Neq0551,
Neq0554 and Neq0568 agents were shown to possess modest
growth inhibitory activity against HCT-116 and MiaPaCa-2
carcinoma cells with GI50 values 400 mM. Selectivity for
cancer cells over MRC-5 broblasts was unremarkable with
maximum cancer selectivity indices achieved for Neq0554 and
Neq0568 of 1.75 and2 respectively (GI50 MRC-5/GI50 MiaPaCa-
2 or HCT-116). AFt-encapsulated test agents showed greater
growth inhibitory activity in cancer cells, compared to the nakedTable 1 Summary of encapsulation eﬃciency (EE) and drug loading
(DL) for cysteine protease inhibitors. Number of molecules of test
agent per AFt capsule was determined by UV-vis spectroscopy. All
measurements were performed in triplicate and the standard deviation
(SD) is provided
Chemical formula N (per AFt) EE (%) DL (%)
Neq0551 C18H17N3O3 117  3 55.2  4.6 14.5  4.4
Neq0554 C17H16F3N5O2 105  2 50.9  10.9 10.1  1.2
Neq0568 C17H27N5O2 226  12 71.2  9.9 14.3  6.8
36702 | RSC Adv., 2019, 9, 36699–36706compounds. In particular, following 72 h exposure to carci-
noma cells, >2.5-fold enhanced Neq0554 potency was achieved
for encapsulated agent; against MiaPaCa-2 cells, GI50 value < 80
mM for AFt-Neq0554 (Fig. 2). AFt-encapsulation of Neq0568
reduced the GI50 value >3-fold in MiaPaCa-2 cells (Table 2).
Importantly, selectivity for cancer cells became more
pronounced for encapsulated agents with GI50 values of >200
mM in non-tumorigenic MRC-5 broblasts.
AFt is internalized by cells by TfR1-mediated endocytosis,25
hence western blot was performed to investigate cellular TfR-1
levels. TfR1 protein expression was detected in lysates
prepared from HCT-116 and MiaPaCa-2 cells; in contrast, TfR1
levels were undetectable in lysates of non-tumorigenic bro-
blasts, inferring disparity in TfR1 expression between cancer
and non-cancer cells (Fig. 2d). Indeed, rapid cell division
increases cellular iron demand and enhanced TfR1 expression
is detected in cancer cells.25 Preferential expression of TfR1 by
actively dividing cells, including normal broblasts, was re-
ported >30 years ago,31 as transferrin is required for cell
proliferation in culture.Table 2 GI50 values for both naked and AFt-encapsulated drugs
tested against the cancer and normal cell lines
Test agent
Mean GI50 values  SD (mM)
HCT-116 MiaPaCa-2 MRC-5
Neq0551 >500 >500 >500
Neq0551-AFt >200 162.2(5.7) >200
Neq0554 358.6(7.7) 230.7(9.1) 404.0(9.7)
Neq0554-AFt 131.0(5.2) 79.5(10.7) >200
Neq0568 231.1(7.8) 393.0(8.1) >500
Neq0568-AFt 168.1(6.5) 125.1(9.8) >200
This journal is © The Royal Society of Chemistry 2019
Fig. 3 (a) Representative cell cycle proﬁles of HCT-116 cells and (b)
histogram of the cell population distribution for control cells and
following treatment with naked and encapsulated Neq0554. The
standard deviation was calculated and was found to be <5%.
Fig. 4 Cathepsin L in vitro activity in HCT 116 and MiaPaCa-2 cells
following 6 h or 24 h exposure to AFt-Neq554. Data were generated
following quantiﬁcation of confocal microscopy images and represent
mean SD$ 3 independent trials (a). Confocal images of HCT 116 and
MiaPaCa-2 cells after 6 h incubation of 50 mM naked and AFt-
encapsulated Neq554, for comparison, images of untreated control
Paper RSC AdvancesTo better understand the mechanism of carcinoma cell
growth inhibition caused by AFt-Neq0554 compared to naked
agent, cell cycle was examined by ow cytometry. Following 48 h
treatment, MiaPaCa-2 and HCT-116 cells were gently per-
meabilized and cellular DNA was stained with propidium iodide
(PI). Although changes in G1, G2 and M phase-events were
modest, the population of cells in S-phase was reduced by 15%
inHCT 116 cells following treatment with AFt encapsulated agent
AFt-Neq0554 (10 mM). These results suggest reduced DNA repli-
cation and cytostasis/quiescence. Also, following exposure of
cancer cells to both naked and encapsulated agents, small but
signicant pre G1 phase populations were observed, indicating
apoptosis. Representative cell cycle proles for HCT 116 (Fig. 3)
show 14% and 26% of pre-G1 events following exposure to 10 mM
and 100 mM AFt-encapsulated Neq 554, respectively.
Clonogenic assays were performed to explore further the
putative cytotoxicity caused by AFt-Neq0554, examining
whether cells surviving exposure to the test agents retain the
ability to form colonies. The clonogenic survival of HCT 116
cells was marginally inhibited (22% and 28%) by 24 h exposure
to 100 mM naked and AFt-encapsulated Neq0554, respectively.
In contrast, MiaPaCa-2 colony formation was dramatically
impeded (>60%) by naked and AFt-encapsulated Neq0554 (100
mM). In both cell lines, AFt-encapsulated Neq554 inhibited
colony formation to a greater extent than naked agent, likely
due to enhanced cellular uptake. That colony formation per-
sisted, strongly indicates a cytostatic response to treatment,
temporary quiescence dependent upon presence of the
compound.This journal is © The Royal Society of Chemistry 2019Cathepsin L inhibition analysis by confocal microscopy
Cells were exposed to diﬀerent concentrations of naked and
encapsulated Neq0554 for 6 and 24 h to examine cathepsin L
inhibition inside live cells. In both cancer cell lines, total
cathepsin L activity was more eﬀectively inhibited following
exposure to AFt-encapsulated agent, compared to naked
Neq0554. AFt alone had no eﬀect on cathepsin L activity. At
treatment concentrations of Neq554 above 25 mM, inhibition of
cathepsin L by AFt-encapsulated agent was >50% aer 6 h
exposure (Fig. 4). Although some recovery of activity was
observed aer 24 h treatment, cathepsin L inhibition >20% did
persist. This trend was also observed inMiaPaCa-2 cells. Of note
was the observation that aer 24 h exposure of cells to naked
Neq0554, no inhibition of cathepsin L was detected in either
cell line, activity equivalent to untreated control cells was
observed (not shown) strongly inferring that AFt-encapsulation
prolonged cathepsin L inhibition, potentially by retaining
intracellular/lysosomal Neq554 for a greater period of time.
All inhibitors used here were designed based on a dipeptidyl
nitrile structure as prototype.19 Using biochemical analysis, we
were able to measure the aﬃnity of these drugs to their
molecular target: cathepsin L. The apparent inhibition constant
Ki0 was determined by non-linear regression to be 7.10  0.04,
7.90 0.04 and 8.10 0.03 for Neq0551, Neq0554 and Neq0568,
respectively. We observed that all compounds were potent
inhibitors of cathepsin L activity based on an in vitro assay, with
Ki0 lower than 10 nM. Biochemical aﬃnity has beencells are also shown (b). All images are 100 mm wide.
RSC Adv., 2019, 9, 36699–36706 | 36703
RSC Advances Papercorroborated with observations of cellular cathepsin L inhibi-
tory activity in real time.
Discussion
The loading of the cysteine protease inhibitor in AFt nanocages
was performed by passive diﬀusion, where agents enter the cage
via channels in the AFt capsule. Following encapsulation, the
samples are puried to remove non-encapsulated drug mole-
cules. We assessed the morphology of encapsulated agents by
DLS and native PAGE, conrming that the external diameter
and surface charge of the AFt remains unchanged following
encapsulation. We also note, that enhanced intracellular
internalisation of AFt-encapsulated agent is strongly supported
by our in vitro studies and confocal microscopy imaging of
cathepsin L inhibition. These observations strongly suggest that
the protein remains unchanged following the encapsulation
process. Hence, we conclude that all molecules detected in our
samples are in the inner cavity of the protein.
The covalent reversible cysteine protease inhibitors used in
this work were reported previously as experimental putative
anticancer agents,18,19 however their selectivity to cancer cell
lines needed to be addressed to reduce potential toxicities and
side eﬀects. All compounds are dipeptidyl nitrile derivatives
(Fig. 1a). The cysteine protease inhibition occurs by interaction
of nitrile group with the sub sites present in the enzyme
structure, promoting the attack of the nitrile group by the
nucleophilic Cys25 in the catalytic pocket of the cysteine
protease.
Based on previous results from our group, the nanomolar
inhibition of the cysteine proteases did not lead to relevant
cytotoxic activity at 100 mM in cell-based assays against the
Leishmania spp. parasites 30 or pancreatic carcinoma cells
(MiaPaCa-2).30,32 Therefore, AFt encapsulation was used to
enhance the cytotoxic potential against cancer cells. Since the
test agents are hydrophobic (Fig. 1a), we envisage that encap-
sulation takes place via passive diﬀusion through the hydro-
phobic channels in the protein cage (Fig. 1b) in which EE > 50%
was achieved for all compounds. Also, the surface charge of the
AFt nanocapsules was not aﬀected following the encapsulation
procedure, suggesting that the molecules are incorporated
within the cavity and are not attached to the protein capsules'
exterior (Fig. 1c), hence the cellular recognition and uptake of
AFt is not expected to be aﬀected by the presence of internalized
agent.
An additional benet of the AFt formulation arises from the
pH sensitivity of the protein capsule,33 which can be employed
for favourable pH controlled drug release under specic
conditions. Our release studies conrmed that at reduced pH
values associated with increased size of the AFt channels (pH
5.5),34,35 the release of the agent is enhanced by a factor of 4
compared to pH 7.4 (Fig. 1d and ESI, Fig. S2†), similar to that
demonstrated for doxorubicin.35 In contrast, markedly reduced
drug release was obtained at physiological pH (Fig. 1d).
Previous reports also indicated long-term retention of encap-
sulated agents at pH 7.34,35 Our results conrm that the drug
encapsulated within AFt nanocages will be preferentially36704 | RSC Adv., 2019, 9, 36699–36706released in acid environments such as those within the cancer
microenvironment and specically, intracellular lysosomes.36
We posit that AFt provides a biocompatible carrier, indeed,
no cytotoxic activity of AFt alone was observed in any of the
studied cell lines (Fig. SI-2†), consistent with work reported
previously.37 In addition, encapsulation of biomolecules into
AFt nanocages has excellent potential in terms of enhanced
drug accumulation, cellular uptake and biological activity.38
AFt is preferentially internalized by cells following TfR1-
mediated endocytosis,25 hence AFt encapsulation of active
agent provides a tool for their selective uptake by cells
expressing TfR1, hence decreasing possible side eﬀects.34
Cellular TfR-1 protein was detected in lysates of HCT-116 and
MiaPaCa-2 cancer cells, and was below detectable levels in non-
tumorigenic broblast MRC-5 cells (Fig. 2a). This diﬀerence in
TfR1 expression is a likely cause of the improved potency
against cancer cells of all test agents aer AFt-encapsulation.
Also, selectivity indices for Neq compounds are clearly
enhanced between cancer and non-cancer cells, as evident from
the dose response curves (Fig. 2b–d). Following exposure of
cancer cells to both naked and encapsulated Neq0554,
increased pre-G1 phase populations were observed (Fig. 3),
indicating apoptosis.39,40
Cell survival and clonogenic expansion are fundamental to
cancer development and metastases.41,42 Clonogenic assays
were therefore performed to explore further putative cytotoxicity
imparted by AFt-Neq0554, examining whether cells surviving
exposure to the test agents retain the ability to form colonies. In
both studied cancer cell lines, AFt facilitated increase of cellular
uptake of the agent led to inhibition of colony formation to
a greater extent than naked agent. Clonogenic survival was
signicantly lower in MiaPaCa-2 compared to HCT-116 cells. In
addition, colonies of reduced size were observed following
treatment of cells with AFt-encapsulated agents. Indeed,
cysteine protease inhibition is expected to decrease cell migra-
tion and invasion,8 key cancer hallmarks essential for
metastasis.
Inhibitors of proteases have shown in vitro and in vivo anti-
cancer activity, promoting benecial eﬀects for the treatment
of tumours.43 Herein, we demonstrate that cathepsin L inhibi-
tion was markedly enhanced in both cell lines aer exposure to
AFt-Neq0554. These observations corroborate a role for TfR1-
mediated uptake of AFt-encapsulated agents and sustained
release of cargo in acidic lysosomes, indicating the signicance
of AFt nanocage-encapsulation to potentiate treatment eﬃcacy
by exploitation of cancer cell upregulation of TfR1. It is note-
worthy that in MiaPaCa-2 cells, where cathepsin L inhibition
persisted for 24 h, clonogenic survival, following 24 h exposure
of cells to AFt-Neq0554 was <40%, thus inferring that the
cysteine protease inhibition is intensied by encapsulation of
the inhibitors in AFt, which traﬃcs cargo directly to the lyso-
somes, where these enzymes predominate.44 Cathepsin L inhi-
bition was demonstrated previously using small molecule
inhibitors,7 antisense RNA45 and (si)RNA.46 The anticancer
activity of AFt-encapsulated dipeptidyl nitrile based inhibitors
is comparable to the activity of other small molecule inhibitors,7
and oﬀers additional benet of pH induced release andThis journal is © The Royal Society of Chemistry 2019
Paper RSC Advancesselective uptake. Inhibition of cathepsin L achieved in this work
is of particular importance for pancreatic cancer treatment,
where cathepsin L is considered to be an independent prog-
nostic marker,47 and its inhibition could be used to reduce
cancer invasion and tumor growth, and merits further investi-
gations in vivo.Conclusions
In conclusion, we have developed a robust method for encap-
sulation of novel Neq cathepsin L inhibitors into AFt nanocages:
>100 Neq0554 molecules were encapsulated per AFt cage
achieving >50% EE. The integrity of AFt nanocages was
preserved as evidenced by DLS and native PAGE. Encapsulated
Neq0554 demonstrated enhanced anticancer activity in vitro
compared to naked agent (3-fold), revealing cancer cell line-
selectivity (2.5-fold), possible consequence of enhanced TfR-1-
mediated endocytosis of AFt-Neq0554. Increased and more
persistent inhibition of cathepsin L in treated cancer cells was
observed following AFt-encapsulation of Neq0554, consistent
with cellular retention and sustained release of Neq0554 in
acidic cytosolic compartments. Release of all Neq cathepsin L
inhibitors, determined under physiological conditions demon-
strated more rapid liberation from AFt capsules in acidic envi-
ronments analogous to those found in lysosomes. We conclude
that AFt-mediated delivery of novel cathepsin L inhibitors is
worthy of further pursuit as a putative anticancer strategy.Conﬂicts of interest
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